{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:12:41Z","timestamp":1792444361188,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006083","name":"American Gastroenterological Association Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"AHRQ","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1053\/j.gastro.2021.07.043","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T10:06:32Z","timestamp":1627985192000},"page":"1443-1459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis"],"prefix":"10.1053","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-9959","authenticated-orcid":false,"given":"Shailja C.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Tepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia P.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Richard M.","family":"Peek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christianne","family":"Roumie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2021.07.043_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis","volume":"153","author":"Hooi","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.043_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.28999","article-title":"Global burden of gastric cancer attributable to Helicobacter pylori","volume":"136","author":"Plummer","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1053\/j.gastro.2021.07.043_bib5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/j.gastro.2018.08.063","article-title":"Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018","volume":"156","author":"Peery","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.043_bib6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.043_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12597","article-title":"Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition","volume":"24","author":"Kato","year":"2019","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2021.07.043_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2019.04.011","article-title":"Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics","volume":"157","author":"Fallone","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.043_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of Helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.043_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection\u2014the Maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.07.043_bib11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.07.043_bib12","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/j.gastro.2020.11.059","article-title":"AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review","volume":"160","author":"Shah","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.043_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1440-1746.2008.05314.x","article-title":"Asia-Pacific consensus guidelines on gastric cancer prevention","volume":"23","author":"Fock","year":"2008","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.043_bib14","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.043_bib15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2217\/pgs.11.4","article-title":"Update on the pharmacogenomics of proton pump inhibitors","volume":"12","author":"Hagym\u00e1si","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1053\/j.gastro.2021.07.043_bib16","article-title":"Effects of CYP2C19 loss-of-function variants on the eradication of H.\u00a0pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials","volume":"8","author":"Tang","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2021.07.043_bib17","doi-asserted-by":"crossref","first-page":"e6489","DOI":"10.1097\/MD.0000000000006489","article-title":"The effect of MDR1 C3435T polymorphism on the eradication rate of H.\u00a0pylori infection in PPI-based triple therapy: a meta-analysis","volume":"96","author":"Li","year":"2017","journal-title":"Medicine"},{"key":"10.1053\/j.gastro.2021.07.043_bib18","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1523-5378.2008.00643.x","article-title":"Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis","volume":"13","author":"Zhao","year":"2008","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2021.07.043_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/17425255.2018.1461835","article-title":"Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine","volume":"14","author":"El Rouby","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1053\/j.gastro.2021.07.043_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41431-019-0480-8","article-title":"Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe","volume":"28","author":"Petrovi\u0107","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1053\/j.gastro.2021.07.043_bib21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/tpj.2012.10","article-title":"Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes","volume":"13","author":"Martis","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"10.1053\/j.gastro.2021.07.043_bib23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2021.07.043_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2021.07.043_bib26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2021.07.043_bib27","first-page":"2880","article-title":"Effects of CYP2C19 and MDR1 polymorphism on the eradication rate of Helicobacter pylori infection in esomeprazole-based triple therapy","volume":"28","author":"Chen","year":"2012","journal-title":"J\u00a0Pract Med"},{"key":"10.1053\/j.gastro.2021.07.043_bib28","first-page":"4","article-title":"Influence of multidrug resistance gene 1 C3435T genetic polymorphism on the eradication of gastric ulcer with Helicobacter pylori infection","volume":"36","author":"Zhang","year":"2013","journal-title":"Chin J Postgrad Med"},{"key":"10.1053\/j.gastro.2021.07.043_bib29","first-page":"6955","article-title":"Influence of MDR1 C3435T polymorphism on the eradication of Helicobacter pylori in patients with gastric ulcer","volume":"34","author":"Shi","year":"2014","journal-title":"Chin J Gerontol"},{"key":"10.1053\/j.gastro.2021.07.043_bib30","first-page":"458","article-title":"Effect of cytochrome P450 2C19 genetic polymorphisms on ef\ufb01cacy of rabeprazole or omeprazole-based triple therapy for eradication of Helicobacter pylori","volume":"25","author":"Jiang","year":"2005","journal-title":"Chin J Dig"},{"key":"10.1053\/j.gastro.2021.07.043_bib31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.dld.2016.01.002","article-title":"Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy","volume":"48","author":"Song","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.gastro.2021.07.043_bib32","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/jac\/dkr217","article-title":"Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial","volume":"66","author":"Liou","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.gastro.2021.07.043_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1523-5378.2007.00588.x","article-title":"One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin","volume":"13","author":"Miehlke","year":"2008","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2021.07.043_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2036.2006.02993.x","article-title":"Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin","volume":"24","author":"Miehlke","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.07.043_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1523-5378.2010.00761.x","article-title":"Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy","volume":"15","author":"Kuo","year":"2010","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2021.07.043_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/MD.0b013e31821c9d1c","article-title":"Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies","volume":"90","author":"Wu","year":"2011","journal-title":"Medicine"},{"key":"10.1053\/j.gastro.2021.07.043_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2036.2003.01659.x","article-title":"High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection","volume":"18","author":"Isomoto","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.07.043_bib38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1017\/S0950268806006613","article-title":"Influence of smoking and CYP2C19 genotypes on H.\u00a0pylori eradication success","volume":"135","author":"Suzuki","year":"2007","journal-title":"Epidemiol Infect"},{"key":"10.1053\/j.gastro.2021.07.043_bib39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1017\/S0950268802008129","article-title":"Smoking and polymorphisms of fucosyltransferase gene Le affect success of H.\u00a0pylori eradication with lansoprazole, amoxicillin, and clarithromycin","volume":"130","author":"Matsuo","year":"2003","journal-title":"Epidemiol Infect"},{"key":"10.1053\/j.gastro.2021.07.043_bib40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7150\/ijms.3.135","article-title":"Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A","volume":"3","author":"Ishida","year":"2006","journal-title":"Int J Med Sci"},{"key":"10.1053\/j.gastro.2021.07.043_bib41","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2169\/internalmedicine.56.7823","article-title":"Randomized trial comparing esomeprazole and rabeprazole in first-line eradication therapy for Helicobacter pylori infection based on the serum levels of pepsinogens","volume":"56","author":"Shimoyama","year":"2017","journal-title":"Intern Med"},{"key":"10.1053\/j.gastro.2021.07.043_bib42","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/j.1572-0241.1999.01285.x","article-title":"Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection","volume":"94","author":"Marchildon","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.043_bib43","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1093\/jac\/dkw118","article-title":"Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial","volume":"71","author":"Hong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.gastro.2021.07.043_bib44","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1111\/j.1440-1746.2009.06047.x","article-title":"Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori","volume":"24","author":"Sugimoto","year":"2009","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.043_bib45","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1046\/j.1365-2036.2001.01063.x","article-title":"Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism","volume":"15","author":"Hokari","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.07.043_bib46","first-page":"255","article-title":"Personalized treatment in the eradication therapy for Helicobacter pylori","volume":"27","author":"Jinda","year":"2011","journal-title":"Int J Mol Med"},{"key":"10.1053\/j.gastro.2021.07.043_bib47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bcpt.12667","article-title":"Effects of genetic polymorphisms of cytochrome P450 enzymes and MDR1 transporter on pantoprazole metabolism and Helicobacter pylori eradication","volume":"120","author":"Karaca","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1053\/j.gastro.2021.07.043_bib48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7326\/0003-4819-136-1-200201010-00008","article-title":"Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H.\u00a0pylori antimicrobial resistance partnership (SHARP) study, 1993\u20131999","volume":"136","author":"Meyer","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2021.07.043_bib49","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.gastro.2021.07.043_bib50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.gtc.2010.08.007","article-title":"Pharmacologic aspects of eradication therapy for Helicobacter pylori infection","volume":"39","author":"Furuta","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1053\/j.gastro.2021.07.043_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/39.1.5","article-title":"The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection","volume":"39","author":"Erah","year":"1997","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.gastro.2021.07.043_bib52","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00228-010-0818-1","article-title":"Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole","volume":"66","author":"Gawro\u0144ska-Szklarz","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2021.07.043_bib53","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/0016-5085(92)90360-B","article-title":"Cytokine inhibition of gastric acid secretion\u2014a little goes a long way","volume":"102","author":"Wolfe","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.043_bib54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/gim.0b013e3182329870","article-title":"Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory","volume":"14","author":"Strom","year":"2012","journal-title":"Genet Med"},{"key":"10.1053\/j.gastro.2021.07.043_bib55","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cpt.2015","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing","volume":"109","author":"Lima","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.07.043_bib56","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/apt.13959","article-title":"Letter: CYP3A4\/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan","volume":"45","author":"Sugimoto","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.07.043_bib57","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3904\/kjim.2018.054","article-title":"Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis","volume":"34","author":"Chang","year":"2019","journal-title":"Korean J Intern Med"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521033382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521033382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:33:20Z","timestamp":1758036800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508521033382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0016508521033382"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2021.07.043","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2021.07.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}